Tenax Therapeutics, Inc. (TENX) Financial Statements (2024 and earlier)
Company Profile
Business Address |
101 GLEN LENNOX DRIVE CHAPEL HILL, NC 27517 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
9/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 2,123,682 | 5,583,922 | 6,712,928 | 5,399,877 | 12,861,954 | 7,727,210 | |||
Cash and cash equivalents | 2,123,682 | 5,583,922 | 6,250,241 | 4,905,993 | 12,367,321 | 1,604,810 | |||
Short-term investments | 462,687 | 493,884 | 494,633 | 6,122,400 | |||||
Receivables | 50,171 | ||||||||
Prepaid expense | 738,927 | 105,078 | 82,578 | 780,952 | 458,286 | 285,512 | |||
Other current assets | 345,856 | ||||||||
Other undisclosed current assets | |||||||||
Total current assets: | 3,208,465 | 5,689,000 | 6,795,506 | 6,180,829 | 13,320,240 | 8,062,893 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 179,503 | 287,692 | 58,778 | 169,448 | ✕ | ✕ | |||
Property, plant and equipment | 7,189 | 7,108 | 5,972 | 6,559 | 8,525 | 9,945 | |||
Long-term investments and receivables | 1,809,428 | ||||||||
Long-term investments | 1,809,428 | ||||||||
Other noncurrent assets | 9,552 | 8,435 | 8,435 | 8,435 | 8,435 | 8,435 | |||
Total noncurrent assets: | 196,244 | 303,235 | 73,185 | 184,442 | 16,960 | 1,827,808 | |||
TOTAL ASSETS: | 3,404,709 | 5,992,235 | 6,868,691 | 6,365,271 | 13,337,200 | 9,890,701 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 1,223,470 | 1,563,978 | 1,998,472 | 2,532,395 | 1,565,669 | 975,167 | |||
Accounts payable | 448,425 | 859,638 | 757,856 | 1,661,054 | 749,814 | 611,861 | |||
Accrued liabilities | 775,045 | 704,340 | 1,240,616 | 871,341 | 815,855 | 363,306 | |||
Other undisclosed accounts payable and accrued liabilities | |||||||||
Debt | 624,302 | 120,491 | |||||||
Other undisclosed current liabilities | 33,673 | ||||||||
Total current liabilities: | 1,847,772 | 1,563,978 | 2,118,963 | 2,532,395 | 1,565,669 | 1,008,840 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 183,589 | 124,166 | 60,379 | ||||||
Long-term debt, excluding current maturities | 124,166 | ||||||||
Liabilities, other than long-term debt | 64,196 | ||||||||
Operating lease, liability | 64,196 | 183,589 | 60,379 | ✕ | ✕ | ||||
Other undisclosed noncurrent liabilities | (183,589) | ||||||||
Total noncurrent liabilities: | 64,196 | 183,589 | 124,166 | 60,379 | |||||
Total liabilities: | 1,911,968 | 1,747,567 | 2,243,129 | 2,592,774 | 1,565,669 | 1,008,840 | |||
Equity | |||||||||
Equity, attributable to parent, including: | 1,492,741 | 4,244,668 | 4,625,562 | 3,772,497 | 11,771,531 | 8,881,861 | |||
Preferred stock | 2,521 | ||||||||
Common stock | 4,584 | 1,262 | 674 | 379 | 141 | ||||
Additional paid in capital | 291,030,237 | 282,736,332 | 250,644,197 | 239,939,797 | 239,572,094 | 222,397,198 | |||
Accumulated other comprehensive income (loss) | (70) | 458 | 516 | (16,193) | |||||
Accumulated deficit | (289,542,080) | (278,494,185) | (246,019,827) | (236,168,436) | (227,801,743) | (213,499,285) | |||
Other undisclosed equity, attributable to parent | 4 | 285 | |||||||
Total equity: | 1,492,741 | 4,244,668 | 4,625,562 | 3,772,497 | 11,771,531 | 8,881,861 | |||
TOTAL LIABILITIES AND EQUITY: | 3,404,709 | 5,992,235 | 6,868,691 | 6,365,271 | 13,337,200 | 9,890,701 |
Income Statement (P&L) (USD)
9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
---|---|---|---|---|---|---|---|---|
Operating expenses | (11,052,643) | (32,728,241) | (9,867,930) | (8,555,264) | (6,893,280) | (9,205,898) | ||
Other operating expense, net | (254,832) | |||||||
Other undisclosed operating income (loss) | 65,711,314 | |||||||
Operating income (loss): | (11,052,643) | 32,728,241 | (9,867,930) | (8,555,264) | (6,893,280) | (9,205,898) | ||
Nonoperating income (Other Nonoperating income) | 9,191 | 18,166 | 160,901 | 79,835 | 366,216 | |||
Interest and debt expense | (4,443) | 247,233 | (1,627) | |||||
Income (loss) from continuing operations: | (11,047,895) | 32,975,474 | (9,851,391) | (8,394,363) | (6,813,445) | (8,839,682) | ||
Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | 32,975,474 | (9,851,391) | (8,394,363) | (6,813,445) | (8,839,682) | |
Other undisclosed net income (loss) | (501,116) | |||||||
Net income (loss): | (11,047,895) | 32,474,358 | (9,851,391) | (8,394,363) | (6,813,445) | (8,839,682) | ||
Other undisclosed net loss attributable to parent | (64,948,716) | (7,330,604) | ||||||
Net loss available to common stockholders, diluted: | (11,047,895) | (32,474,358) | (9,851,391) | (8,394,363) | (14,144,049) | (8,839,682) |
Comprehensive Income (USD)
9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
---|---|---|---|---|---|---|---|---|
Net income (loss): | (11,047,895) | 32,474,358 | (9,851,391) | (8,394,363) | (6,813,445) | (8,839,682) | ||
Comprehensive income (loss): | (11,047,895) | 32,474,358 | (9,851,391) | (8,394,363) | (6,813,445) | (8,839,682) | ||
Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (70) | 19,703,310 | 16,788,784 | 20,940,785 | 17,676,839 | |||
Comprehensive income (loss), net of tax, attributable to parent: | (11,047,895) | 32,474,288 | 9,851,919 | 8,394,421 | 14,127,340 | 8,837,157 |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.